CRISPR/Cas9 approaches were used to generate stem cell leukemia/lymphoma syndrome cells null for Interleukin receptor associated kinase 1 and interferon gamma which were introduced into syngeneic hosts through tail vein injection.
[Molecular Cancer]
Sorry, but the selected Zotpress account can't be found.